| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/24/2001 | US6265564 Expressed ligand-vascular intercellular signalling molecule |
| 07/24/2001 | US6265563 Nucleotide sequences probes for use as diagnostic tools and drug screening |
| 07/24/2001 | US6265560 Nucleotide sequences coding enzymatic polypeptide associated with signal transducton; for diagnosis, prevention, and treatment of inflammation, arthritis and physiological defects |
| 07/24/2001 | US6265550 Antibody; for use in the diagnosis, prevention, and treatment of cancer, inflammation, and insulin response defects |
| 07/24/2001 | US6265547 Polypeptide for use in diagnosis, treatment, and prevention of cancer, nervous system disorders |
| 07/24/2001 | US6265543 Polypeptide for the treatment of eye disorders, tumors, cancer, psoriasis, trauma, psychological, burns and ulcers |
| 07/24/2001 | US6265444 Ophthalmic composition |
| 07/24/2001 | US6265435 Topical applying loop diuretic in aqueous solution |
| 07/24/2001 | US6265429 Administering phosphodiesrterase inhibitor |
| 07/24/2001 | US6265425 Side effect reduction; retinoic acid metabolism blocking agent |
| 07/24/2001 | US6265420 Aftertreatment; sustained release |
| 07/24/2001 | US6265414 Treating sleep disorders using desloratadine |
| 07/24/2001 | US6265412 Mixture with antihistamine |
| 07/24/2001 | US6265393 Continuous coadministration of low doses of an estrogen agent and a progestin agent to maintain an induced state of oligomenorrhea or amenorrhea in an afflicted woman. |
| 07/24/2001 | US6265386 In a patient undergoing treatment with an aminoglycoside antibiotic |
| 07/24/2001 | US6265385 Topoisomerase II poison and bis-dioxopiperazine derivative combination therapy |
| 07/24/2001 | US6265188 Nucleotide sequence coding a enzymatic polypeptide; for use as a wound healing agent; for prevention of bacterial infection |
| 07/24/2001 | US6265184 Polynucleotides encoding chemokine receptor 88C |
| 07/24/2001 | US6265175 Incubating components comprising neuroblast and composition to be tested for ability to stimulate or inhibit proliferation or differentiation of the neuroblast to allow composition to bind to neuroblast, culturing, detecting effect |
| 07/24/2001 | US6264991 Administering drug in polymer microsphere |
| 07/24/2001 | US6264984 Effervescent histamine H2 antagonist composition |
| 07/24/2001 | US6264980 Transdermal resorption of active substances from supercooled masses of levulic acid |
| 07/24/2001 | US6264975 Methods of hydrating mucosal surfaces |
| 07/24/2001 | US6264955 Ferrichrome transport ATP-binding protein |
| 07/24/2001 | US6264948 Methods and compositions for inhibiting tumor cell growth |
| 07/24/2001 | US6264947 Genetic engineering; therapy for cancer, autoimmune diseases, reproduction, antiinflammatory agents |
| 07/24/2001 | US6264917 Targeted ultrasound contrast agents |
| 07/24/2001 | CA2331847A1 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors |
| 07/24/2001 | CA2193454C Bioadhesive pharmaceutical composition for the controlled release of active ingredients |
| 07/19/2001 | WO2001051673A1 Methods and compositions for inhibition of membrane fusion-associated events, including hiv transmission |
| 07/19/2001 | WO2001051666A1 Methods for diagnosing and treating heart disease |
| 07/19/2001 | WO2001051642A2 Dna modification proteins |
| 07/19/2001 | WO2001051641A1 Irak-4: compositions and methods of use |
| 07/19/2001 | WO2001051638A2 Drug metabolizing enzymes |
| 07/19/2001 | WO2001051636A2 Secreted proteins |
| 07/19/2001 | WO2001051635A2 Novel stra6 polypeptides |
| 07/19/2001 | WO2001051619A2 Genetically modified fibroblast cell |
| 07/19/2001 | WO2001051523A2 Anti-angiogenic proteins and fragments and methods of use thereof |
| 07/19/2001 | WO2001051519A2 Potassium channel mutants of the saccharomyces cerevisiae yeast and the use thereof for the screening of eukaryotic potassium channels |
| 07/19/2001 | WO2001051463A1 Glyburide composition |
| 07/19/2001 | WO2001051453A1 Racemic and optically pure metabolites of sibutramine, their preparation, compositions comprising them and their use as dopamine reuptake inhibitors |
| 07/19/2001 | WO2001051196A1 Templating of solid particles by polymer multilayers |
| 07/19/2001 | WO2001051087A2 Novel treatment for eye disease |
| 07/19/2001 | WO2001051081A1 In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |
| 07/19/2001 | WO2001051074A1 Methods for treating pancreatic disorders |
| 07/19/2001 | WO2001051068A1 Method and device for increasing and/or decreasing the concentration of immunomodulatory-active substances in substance mixtures |
| 07/19/2001 | WO2001051055A2 Pharmaceutical compositions containing steroidal structures and uses thereof |
| 07/19/2001 | WO2001051053A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| 07/19/2001 | WO2001051051A2 AGENTS, SUCH AS NICOTINAMIDE OR cADPR FOR THE TREATMENT OF SKIN DISORDERS |
| 07/19/2001 | WO2001051050A1 Novel substituted benzimidazole dosage forms and method of using same |
| 07/19/2001 | WO2001051049A1 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
| 07/19/2001 | WO2001051048A1 Use of epigallocatechin-gallate for inhibiting angiogenesis |
| 07/19/2001 | WO2001051043A2 Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols |
| 07/19/2001 | WO2001051042A2 Treatment of diabetic ulcers |
| 07/19/2001 | WO2001051040A1 Osmotic device containing alprazolam and an antipsychotic agent |
| 07/19/2001 | WO2001051014A1 Pharmaceutical and cosmetic carrier or composition for topical application |
| 07/19/2001 | WO2001051003A2 Use of lipid conjugates in the treatment of disease |
| 07/19/2001 | WO2001050987A2 Treatment of hepatitis c using hyperthermia |
| 07/19/2001 | WO2001050881A2 Process and composition for controlling fecal hair excretion and trichobezoar formation |
| 07/19/2001 | WO2001050873A1 Thickened oil compositions of edible oil |
| 07/19/2001 | WO2001014414A3 Human abc2 transporter and uses thereof |
| 07/19/2001 | WO2001013933A3 Agents for the enhanced oxygen delivery in mammals |
| 07/19/2001 | WO2001006261A3 Screening for therapeutic agents being scap antagonists |
| 07/19/2001 | WO2001005969A3 Electron transfer proteins |
| 07/19/2001 | WO2001002549A3 Homomeric and heteromeric ampa receptors |
| 07/19/2001 | WO2001001998A3 Treatment of endometriosis with antileukoprotease |
| 07/19/2001 | WO2000071703A3 Inhibition of histone deacetylase |
| 07/19/2001 | WO2000064485A9 Specifically targeted catalytic antagonists and uses thereof |
| 07/19/2001 | WO2000040229A3 Synergistic tumorcidal response induced by histamine |
| 07/19/2001 | WO2000025808A9 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists |
| 07/19/2001 | WO1999060869A8 Sitostanol formulation with emulsifier to reduce cholesterol absorption |
| 07/19/2001 | US20010008933 Novel disulfides and thiol compounds |
| 07/19/2001 | US20010008905 Administering a compound such as hydroxyurea to deplete the intracellular pool of deoxyribonucleoside phosphate |
| 07/19/2001 | US20010008896 Treatment ofsexual disorders |
| 07/19/2001 | US20010008894 Lipid-lowering quinazoline derivative |
| 07/19/2001 | US20010008889 Anticonvulsant containing composition for treating neuropathic pain |
| 07/19/2001 | US20010008888 Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin |
| 07/19/2001 | US20010008884 Administering to the patient a combination of antidepressant or a monoamine oxidase inhibitor, vitamin B12, and precursor or inducer of a neurotransmitter, e.g. L-phenylalanine |
| 07/19/2001 | US20010008641 Containing creatine monohyrate, glutamine, taurine, whey and minerals |
| 07/19/2001 | US20010008638 Nutritional supplement comprising at least one prohormone and at least one anti-estrogen compound in a time-release dosage form |
| 07/19/2001 | US20010008632 Aqueous medicament preparations for the production of propellent gas-free aerosols |
| 07/19/2001 | DE10001785A1 Use of NK-1 receptor antagonists for treatment of restless legs syndrome |
| 07/19/2001 | CA2406722A1 Dna modification proteins |
| 07/19/2001 | CA2397481A1 Irak-4: compositions and methods of use |
| 07/19/2001 | CA2397340A1 Drug metabolizing enzymes |
| 07/19/2001 | CA2397334A1 Secreted proteins |
| 07/19/2001 | CA2397207A1 Novel stra6 polypeptides |
| 07/19/2001 | CA2397068A1 Pharmaceutical and cosmetic carrier or composition for topical application |
| 07/19/2001 | CA2397030A1 Methods for treating pancreatic disorders |
| 07/19/2001 | CA2396996A1 Genetically modified fibroblast cell |
| 07/19/2001 | CA2396950A1 Racemic and optically pure metabolites of sibutramine, their preparation, compositions comprising them and their use as dopamine reuptake inhibitors |
| 07/19/2001 | CA2396384A1 In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |
| 07/19/2001 | CA2396330A1 Methods for diagnosing and treating heart disease |
| 07/19/2001 | CA2396235A1 Anti-angiogenic proteins and fragments and methods of use thereof |
| 07/19/2001 | CA2396214A1 Osmotic device containing alprazolam and an antipsychotic agent |
| 07/19/2001 | CA2396120A1 Treatment of diabetic ulcers |
| 07/19/2001 | CA2396098A1 Pharmaceutical compositions containing steroidal structures and uses thereof |
| 07/19/2001 | CA2396071A1 Thickened oil compositions of edible oil |
| 07/19/2001 | CA2395567A1 Novel treatment for eye disease |
| 07/19/2001 | CA2366621A1 Use of epigallocatechin-gallate for inhibiting angiogenesis |